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Background: Malaria presents a considerable threat to public health. Histidine-rich protein 2 (HRP 2) is the major
protein released into human blood upon infection by Plasmodium falciparum. In this study, we aimed to evaluate
the immunogenicity of HRP 2 exon II and the efficacy of novel monoclonal antibodies (mAbs) against HRP 2 for
Point-of-Care Test (POCT).
Methods: The recombinant protein was expressed in soluble form in E. coli and used to immunize mice for mAb
production. Two IgG1 mAbs (1A5 and 1C10) with high affinity, specificity and sensitivity for both native and
recombinant HRP 2 were selected after fusion of mouse spleen with myeloma cells. The affinity constant of 1A5
and 1C10 were 7.15 and 4.91 × 10-7 L/mol, respectively. Subsequently, an immunochromatograhic assay was used
for screening of clinical samples in endemic regions of China and Myanmar.
Results: The immunochromatographic test retrospectively showed an overall sensitivity of 99.07%, and specificity
of 100%. Sensitivity at parasite densities < 200, 200–2000, and > 2000 parasites/μL was 87.5, 98.7, and 100%,
respectively.
Conclusions: These results suggest that HRP 2 exon II contains immunogenic sites similar to those of the native
antigen and can be used for the development of mAbs suitable for malaria diagnosis in endemic communities.
Keywords: Malaria, Histidine-rich protein 2 exon II, Monoclonal antibodies, Point-of-care test,
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Malaria, a disease caused by Plasmodium species, is one
of the oldest and largest health challenges affecting 40%
of the world population [1]. There were an estimated
627, 000 malaria deaths in 2012, including 91% in Africa,
mainly caused by P. falciparum infection, the most lethal
malarial plasmodia responsible for the cerebral form of
the disease. Approximately 86% malaria deaths are chil-
dren under 5 years of age [2-4]. These estimates rank
malaria as one of the top three killers among infectious* Correspondence: keren_kang@hotmail.com
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prevalence rates in most parts of China and Myanmar
have been brought under control, very high transmission
rates still remain in certain regional communities [5].
Due to the economic boom in China, cross border trans-
mission has resulted in increasing malaria incidence in
recent years. Current economic globalization trends
coupled with marked movement of people have acceler-
ated the incidence of Plasmodium related cases with
increased antimalarial drug resistance in Southeast Asia,
including China [5]. The Yunnan Province alone counts
over ten million cases of malaria among border and im-
migration officers, an indication of the prevalence of mal-
aria at both sides of the border. Continuous migration of
the population in border areas makes it extremely difficulthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Geographical distribution of malaria endemic areas in China
and Myanmar. 1, Henan Province (n=90); 2, Yunnan Province (n=202);
3, Myanmar (n=224).
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recent years have also shown imported cases of malaria in
Henan, Hebei, Fujian, Chongqing, Shanghai, Jiangxi and
among others [6].
Inaccurate and ineffective diagnosis of P. falciparum
in these regions has resulted in drug resistant species,
pointing to the need for improved diagnosis and moni-
toring of the disease. The total eradication of malaria is
one of the urgent aims of the United Nations Millen-
nium Development Goals. The methods recommended by
WHO for P. falciparum diagnosis include microscopic
examination, immunological tests, and PCR methods [7-9].
Since the launch of WHO’s T3 initiative in 2012, all
malaria-endemic and donor countries should ensure that
every suspected case of malaria is tested and treated,
[10] requiring increased developent of rapid diagnostic
tests (RDTs). Hence the use of fast, accurate, and easy
on-site detection methods and reagents as monitoring
medical tools for early diagnosis and treatment of mal-
aria in regions of high transmission and prevalence is
particularly important. Several detection antibodies against
different Plasmodium antigens have been described, of
which Plasmodium falciparum specific histidine-rich
protein 2 (HRP 2), and Plasmodium lactate dehydrogen-
ase (pLDH) and aldolase are common to all four Plas-
modium species [11]. The PfHRP 2 gene is located on
chromosome 8 of the parasite and comprised of both
exons I and II, encoding a 309-amino acid protein. Se-
quence variations among the different strains range be-
tween 800 to 1300 base pairs. The PfHRP exon II alone
encodes 287 amino acids composed of 34.5% histidine and
35 repeats of the tripeptide His-His-Ala sequences. HRP 2
is released upon rupture of parasitized erythrocytes at
late-stage [12] and is capable of reversing the tightly bal-
anced activities of anticoagulant factors that maintain
homeostasis [13].
The most convenient technique for clinical diagnosis of
malaria is the use of rapid diagnostic test kits, which
depends on the use of mAbs against the HRP 2 antigen.
These tests are particularly important since they can be
used in field diagnostics (point-of-care test, POCT) to
screen large populations without the requirement of trained
laboratory personnel or equipment. Several tests targeting
HRP 2 are available, with various specificities, sensitivities,
and temperature tolerances, illustrating the difficulties and
challenges facing current RDTs [14]. The difficulties asso-
ciated with RDTs include genetic variability in the HRP 2
gene and the persistence of antigens in the bloodstream
following the elimination of parasites [14]. For instance,
ParaSight F, a sensitive, specific, simple, and fast dipstick
assay, uses mAb IgG1, a subclass of IgG [15,16]. However,
HRP 2-based RDTs have given false-positive results and
there has been some debate as to the cause of these false
positives [14]. Therefore, the development and productionof mAbs with high affinity, specificity and sensitivity will
help facilitate its use as POCT.
In this study, we aimed to express the HRP 2 exon II anti-
gen retaining the essential epitopes that can serve as immu-
nogens for use in developing mAbs against HRP 2 for
POCT immunochromatographic assay, according to guid-
ing principles formulated by the WHO [10]. The results of
assays were compared with those of microscopic examin-
ation known as gold standard for clinically screening of mal-
aria samples in endemic regions of China and Myanmar.Methods
Sample collection and reference samples
Clinical samples (n=516) were collected between 2008
and 2012 from patients (6–50 years old) with fever and
suspectable for malaria from Henan (n=90) and Yunnan
(n=202) provinces of China (total n=292) and from
Myanmar (Burma) region (n=224), where malaria is en-
demic and is caused mainly by Plasmodium falciparum
as shown in Figure 1. The study was approved by the
ethics committee of Yunnan Institute of Parasitic Dis-
eases. All participants or legal guardians signed informed
consent before participant enrolment and sample collec-
tion. Complete anonymity was maintained at each stage
of the study. The research has been also approved by the
national engineering laboratory of point-of-care testing
(Wondfo Biotech company, Guangzhou, China).
The diagnosis of malaria follows Diagnostic Criteria for
Malaria issued by the Ministry of Health of the People's
Republic of China. Patients were included if they ①came
from relatively serious malaria epidemic area and ②suf-
fered from fever of unknown origin. Patients were excluded
if they ①suffered from vivax malaria or ②had mixed infec-
tions. The samples were confirmed as single malignant
malaria infection by microscopic examination of thick
blood smear.
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mately 5 mL of blood from adult subjects and 3 mL
from minor subjects by venipuncture. Thick and thin
blood films were prepared in duplicate using two drops
of blood for each sample. The remaining blood was pre-
served at −20°C in EDTA tube. Thick blood films were
stained with 10% Giemsa and microscopic examined by
experienced technicians.
Positive references provided by WHO were divided
into 5 geographical areas, comprising Africa (Benin I
and Nigeria XII), the Americas (Santa Lucia), Australia
(Papua New Guinea-FC27/A3) and Southeast Asia
(Philippines- PH1).Expression and purification of HRP 2 protein
Plasmodium falciparum genomic DNA was extracted
from clinical blood samples provided by Prof. Hui Liu
(Yunnan Provincial Institute of Parasitic Diseases, Simao,
Yunnan, China), using QIAamp DNA Mini Kit (QIAGEN,
Germany). Pair of oligonucleotide primers was designed,
complementary to forward and reverse strands of the
HRP 2 exon II based on the sequence obtained from Gen-
Bank (U69551.1). The forward primer was HRP 2-F: 5׳-T
ATACATATGAATAATTCCGCATTTAATAATAACT-3׳,
and the reverse primer HRP 2-R: 5׳-TACAGTCGACATA
GACGTACTTCTTTTCGTAAG-3׳. The forward and re-
verse primers were designed to contain NdeI and XhoI
restriction sites, respectively. Restriction endonucleases
(NdeI and XhoI), DNA markers and PCR mix were pur-
chased from Dongsheng Biotech Company (Guangzhou,
China), while the T4 DNA Ligation mix was obtained
from TaKaRa Biotech Co. Ltd (Dalian, China). The HRP 2
gene was cloned into a pET30a vector and transformed
into CaCl2 competent E. coli BL21 (DE3) cells [17]. pET-
30a plasmid and BL21 (DE3) cells were provided by
Prof. Jufang Wang of South China University of Tech-
nology. Starter culture was grown overnight at 37°C in
5 ml LB medium, supplemented with kanamycin
(50 mg/L). This stationary phase culture was used to
inoculate 1 L LB medium to an OD600 of 0.6. The latter
culture was inducted with 1 mM IPTG for target pro-
tein expression at 30°C and 225 g, overnight. Cells were
harvested by centrifugation at 8000 g for 3 min and cell
pellets resuspended in lysis buffer consisting of 100 mM
Tris–HCl, pH 9.6. Cell suspensions were ultrasonicated
on ice and centrifuged at 4°C at 12000 g for 15 min. The
resulting supernatants were purified on a Hi-Trap Ni2+
column (GE, USA) using AKTA Purifier and the puri-
fied recombinant HRP 2 protein (rHRP 2) fractions visual-
ized on 12% Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) [18]. The protein samples
(>90% purity) were purified by dialyzing against 50 mM
carbonate buffer, pH 9.6.Animal immunization and mAb production, screening,
purification and characterization
Six-to-eight-weeks-old Balb/c mice were purchased from
the Animal Laboratory Center of Sun Yat-sen University
(Guangzhou, China). All experimental procedures were
in compliance with the Guide for Care and Use of Labo-
ratory Animals (NIH version, revised 1996). All animals
were allowed free access to food and water.
MAbs were produced as described by Kohler and
Milstein [19] and screened by indirect ELISA described
below. The IgG fractions were prepared by ammonium sul-
fate precipitation and purified on Protein A column. The ti-
ters were determined by indirect ELISA and mAb isotyping
was carried out using mouse mAb isotyping kit purchased
from Sigma-Aldrich (St. Louis, MO, USA) according to the
manufacturer’s instructions. The specificity of monoclonal
antibodies was determined by their binding affinity to both
rHRP 2 and P. falciparum infected blood samples. SDS-
PAGE was carried out on 12% separating and 5% stacking
gels, followed by protein transfer to polyvinylidene fluor-
ide (PVDF) membranes. SuperSignal West Pico Chemilu-
minescent Substrate (Thermo Fisher Scientific Inc., USA)
was applied for visualization. Determination of antibody
affinity was carried out by a noncompetitive ELISA as de-
scribed by David Beatty [20] with little modifications.
Indirect ELISA
Microtiter plates were coated with 1 μg/ml of purified
rHRP 2 in coating buffer (0.05 M carbonate buffer,
pH 9.6). After overnight incubation at 4°C, plates were
rinsed with washing solution (0.15 M PBS 0.1% Tween 20,
pH 7.4) and blocked with 3% bovine serum albumen (BSA)
for 2 h. 100 μL hybridoma cell supernatants were added to
wells and incubated for 1 h at 37°C. After washing, 100 μL
goat anti-mouse IgG-HRP (ZSGB-BIO, China, 1:20000)
antibodies were dispensed into each well followed by 1 h
incubation at 37°C. The enzymatic reaction was visualized
using TMB substrate with hydrogen peroxide and stopped
with 2 M Sulphuric acid. Optical density (OD) was mea-
sured spectrophotometrically at 450 nm. Samples were
considered positive with OD of cell supernatant (P) to
negative control (N) ratios greater than 2.1.
Sandwich ELISA
Purified mAbs were paired, labeled with periodate oxida-
tion and sandwich ELISA was performed as described
before [21]. The lower the OD, the two strains of anti-
body antigen epitope closer; the higher the OD value,
illustrate both the antigen epitope is more far.
Establishment of POCT lateral immunochromatographic
assay
HRP 2 specific mAb 1A5 (1.5 mg/ml) and goat-anti-
mouse IgG (2.0 mg/ml) were diluted in 0.05 M carbonate
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and 1 μl/cm2 to form test and control lines, respectively.
The prepared nitrocellulose membranes were kept in a
dry pack at 30°C and 30% humidity. 1C10 antibody were
conjugated to colloidal gold as described by Oliver [22]
and sprayed on glass fiber at 12 μL/cm2. The strip was
assembled by placing 0.7 cm of antibody-gold conjugate
glass fiber a few centimeters from the test line and 4 mm
wide test strips were cut. Test strip preparation was done
in a good manufacturing practice (GMP) workshop.
Sample evaluation and sensitivity calculation
Positive control samples provided by WHO were evalu-
ated alongside 516 clinical samples and test results were
compared with microscopic examinations. About 5 μL
of each sample was applied to the sample site and three
drops of dilution buffer added. Test strips were observed
for 15 min and results were interpreted as positive when
both the control and test lines turned red and negative if
only the control line turned red. In cases where the con-
trol line did not appear, the results were considered invalid
and the assay repeated.
Sensitivity of the test equals the ratio of total positives to
total number of samples, specificity equals the ratio of total
negatives to total number of samples, positive predictive
value equals the proportion of the number of positive cases
detected among actual positives cases and negative predict-
ive value equals the proportion of the number of negative
cases detected in relation to actual negatives.Statistics
Statistical analysis was performed with SPSS 18.0 soft-
ware (SPSS, Chicago, IL). Data obtained from both
microscopic examination and immunochromatographic
test were analyzed. Sensitivity and specificity of the assay
and how it compares with the standard microscopic exa-
mination was analyzed. Agreements between both data
were computed by Kappa statistics. Differences were
considered statistically significant at p < 0.05.Figure 2 Western blot analysis of mAbs. Recombinant HRP 2
(0.5 μg) and nature HRP 2 were run on SDS-PAGE. The gel was
blotted onto a nitrocellulose membrane and probed with 0.5 μg/ml
of mAb 1A5 and 1C10. Lane M: molecular marker; Lane 1 and 2:
rHRP 2 probed with mAb 1A5 and 1C10, respectively; Lane 3 and 7:
Human blood serum probed with mAb 1A5 and 1C10, respectively;
Lanes 5 and 6: Plasmodium falciparum cell culture supernatants
probed with mAb 1A5 and 1C10, respectively; Lane 4 and 8: pLDH
antigen (0.5 μg) probed with mAb 1A5 and 1C10, respectively.Results
Malaria diagnosis
Microscopic inspection showed that most samples were
positive for only Plasmodium falciparum infections, with
no mixed infections detected (n=322) including 60/90
(66.7%) samples from Henan, China, 105/202 (52.0%)
samples from Yunnan, China and 157/224 (70.1%) from
Myanmar. Negative Plasmodium falciparum blood sam-
plesn=194) were also assessed by thick and thin smear
microscopic examinations and confirmed to be Plasmo-
dium falciparum negative, including 30/90 (33.3%) samples
from Henan, China, 97/202 (48.0%) samples from Yunnan,
China and 67/224 (29.9%) from Myanmar.mAbs 1A5/1C10 efficiently recognize recombinant and
nature HRP 2
The 831 bp DNA fragment was transformed into E. coli
BL21 to express soluble recombinant HRP 2 exon II
after IPTG induction. Hybridomas were developed using
mouse spleen cells screened by indirect ELISA. After
three rounds of limiting dilution, 5 stable cell lines pro-
ducing mAb against PfHRP 2 were selected. mAbs from
the 5 cell lines were paired in a sandwich ELISA (totally
10 pairs) and 1A5/1C10 pair was chosen for further ana-
lysis and detection of clinical samples. The titer values
for mAb 1A5 and 1C10 were greater than 106 and their
affinity constants were 7.15 and 4.91 × 10−7 L/mol, re-
spectively. Both mAbs were of the IgG1 isotype. Figure 2
shows the immunoblot analysis of mAbs 1A5 and 1C10
probing rHRP 2, human blood serum, Plasmodium falcip-
arum cell culture supernatants and pLDH antigen. The
result showed that mAbs 1A5 and 1C10 recognize recom-
binant and nature HRP 2 sensitively and spectively.
Lateral immunochromatographic test strip evaluation and
accuracy
All positive references were examined retrospectively with
both microscopy and the immunochromatographic assay.
Differences in detection levels were noted (Figure 3). The
different positive references showed varied concentrations
of HRP 2 antigen that resulted in significantly different
detection levels (Table 1).
Screening of clinical samples
A total of 516 blood samples collected from 6–50 years
old patients were examined. The newly developed test
kit detected 164 of the 165 positive samples originating
from China (sensitivity of 99.39%), with no false positives
in the 127 negative samples examined. In samples col-
lected in Myanmar area, a total of 157 positive and 67
Figure 3 POCT lateral immunochromatographic assay. A, a
representative of negative control in which only the control line
turns red; B, a representative of positive control in which both the
control and test lines turn red; C, a representative of sample in which
both the control and test lines turn red and indicate that this sample is
P. falciparum positive.








Sensitivity (95% CI) 99.39 98.72 99.07
Specificity (95% CI) 100 100 100
Positive predictive value (%) 100 100 100
Negative predictive value (%) 99.22 97.10 98.48
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98.72%. Three false negatives were recorded. These results
are summarized in Table 2. Parasitemia density higher
than 2000 and 200 parasites/μL for first time and recur-
rent cases, respectively, are evidence of higher infection
rate. The POCT method was also used to screen clinical
samples with parasites both below 200 and above 2000
parasites/μL in order to compare their sensitivity rate.
Among the 16 clinical blood samples with less than 200
parasites/μL, two false negatives were obtained while only
one false negative was recorded among the 77 microscop-
ically positive samples with parasite density of 200–1999
parasites/μL (Table 3). There was 100% sensitivity for
blood samples with higher densities above 2000 parasites/
μL (Table 3).
Discussion
Malaria is a major public health problem worldwide and
its total eradication is one of the urgent aims of theTable 1 mAbs 1A5 and 1C10 double antibody sandwich
assay detection of positive reference samples from WHO
Sample HRP 2 Sequence information Detection level
Benin I A +
Santa Lucia B(high) +++
Nigeria XII B(medium) ++
FC27/A3 B(low) ++
PH1 C +
A, B and C represent different HRP 2 sequences.
“+” indicates weak positive, “+ +” indicates fairly positive and “+ + +” indicates
strong positive.United Nations Millennium Development Goals. Hence
the use of fast, accurate, and easy on-site detection methods
and reagents as monitoring medical tools for early diagnosis
and treatment of malaria in regions of high transmission
and prevalence is particularly important. However, the per-
formance of existing HRP 2 tests in areas of intense malaria
transmission varies by age and prevalence of P. falciparum
infection [14]. The particularly low specificity among chil-
dren results in over-estimation of malaria infection preva-
lence in this group [23].
In the current study, we aimed to evaluate the im-
munogenicity of HRP 2 exon II for use in developing
mAbs against HRP 2 for POCT. We have successfully
expressed recombinant HRP 2 exon II in E. coli and
purified its full amino acid sequence. After administra-
tion of the purified rHRP 2 antigen in mice followed by
fusion of mouse splenocytes with myeloma cells, two dif-
ferent hybridomas (1A5 and 1C10) producing anti-HRP
2 mAbs were selected and used for the preparation of
ascitic fluids in mice. After purification of ascitic fluids
by ammonium sulfate precipitation and Protein A column,
specificity of 1A5 and 1C10 was assessed by immunoblot:
both antibodies exhibited remarkable specificity for detec-
tion of both recombinant and native P. falciparum HRP 2
antigen, binding to no other protein in human blood
serum.
A noncompetitive ELISA method was used in the
determination of antibody affinity. We found association
constant (Ka) values of 7.15 x 10−7 and 4.91 × 10−7 (unit)
for 1A5 and 1C10, respectively, an indication of the high
binding affinity of these two mAbs. The high affinity ob-
served for the expressed exon II region of PfHRP 2 sug-
gests that epitopes are conserved in this region. Therefore,
the recombinant PfHRP 2 protein developed in this study
can serve as immunogen to facilitate the production of
high affinity and high specificity mAbs for use in clinicalTable 3 Comparison of immunochromatographic test
strips and microscopic examination of thick blood smear
Parasite density Sample size (n) Positives Detection rate
<200 16 14 87.50%
200-1999 77 76 98.70%
>2000 229 229 100%
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etic diversity of HRP 2 affects the performance of the
HRP 2-based RDT [24].
Microscopic examination of both thick and thin blood
smears is a traditional detection method and hence
considered the gold standard for malaria diagnosis.
However, due to its complicated operation and the re-
quirement of experienced laboratory technicians, field
application is limited. POCT, a new concept for rapid
diagnosis of clinical samples developed in recent years
is very crucial. POCT is based on small, portable, easy to
operate, fast, accurate, and effective devices for on-site
monitoring of infections. Sensitivity of HRP detection kits
is affected by several factors including the quality of mAbs
used, immunogenic response of B cells to the different
epitopes of HRP 2 protein [25], and the polymorphism
observed in the HRP gene sequence. The HRP antigen
contains numerous repeats of histidine and alanine amino
acids. The tripeptide repeat Ala-His-His in HRP 2 is quite
conserved, while Ala-Ala-Asp which also has only slight
variations can be detected by mAbs specific to HRP 2 in
different isolates [26-28].
The lateral immunochromatographic assay was devel-
oped with the two HRP 2 specific mAbs and used for
testing of blood samples collected from high endemic
regions in China and Myanmar. There was a strong agree-
ment between the immunochromatographic test results
and microscopic examination among the 322 positive and
194 negative samples tested (K=0.9955 at p < 0.001). The
observed sensitivity and specificity were 99.07 and 100%,
respectively (Table 2). In clinical samples, there were false
negatives at low parasite densities. However, samples with
parasite densities above 2000 parasites/μL were detected
with 100% sensitivity (Table 3).
mAbs with acceptable sensitivity, specificity and high
affinity for the PfHRP 2 antigen are prerequisite for accur-
ate diagnosis of P. falciparum infections. Because of the
limited supply of mAbs, it is very likely that most HRP 2-
based RDTs use similar or identical antibodies. Existing
HRP 2-based RDTs are known to yield false-positive results
[14]. Therefore, development of new mAbs with high sensi-
tivity for use in HRP 2 diagnostic test kits is very import-
ant. We have evaluated two such mAbs and experiments
are underway to further define the specific epitopes recog-
nized by these mAbs and develop serological test kits
using these mAbs. The newly designed RDTs combin-
ing two different mAbs would improve the detection
of malaria worldwide given that the epitopes involved
are common to all P. falciparum, resulting in saved lives
and reduced occurrence of parasite resistance.
Conclusion
The Plasmodium falciparum HRP 2 exon II contains im-
munogenic sites similar to those on the native antigen.These immunogenic sites can effectively be utilised for
the development of highly sensitive and specific mAbs
to facilitate malaria diagnosis in endemic communities.
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